Bayer is going through a tumultuous phase, with its stock experiencing a continuous slump. There is an all-time
low in share value seen in the past 20 years due to a dismal forecast for 2025 earnings and several U.S court defeats over the controversial Roundup case. These setbacks caused a fall in Bayer shares as much as by 8% after a
$2.1B fine from the US jury. Furthermore, Bayer faces scrutiny from market regulators over the share drop. An improvement is foreseen starting FY26, despite a cautious FY25 amid a Q4 loss. Despite all these setbacks, Bayer has received
FDA's complete approval for a drug meant for a certain type of cancer. There is significant pressure on the CEO to manage the wave of negative news. Despite litigation, debt, and decline, Bayer appears to be an attractive buy to some investors purely as a contrarian investment. Bayer's managerial share purchase is seen as a commitment to shareholder alignment. Bayer's shares have seen a surge after few legal victories in the U.S against Roundup cancer claims. However, the near-term outlook remains dominated by generic pressures and crop science uncertainty. There is also discussion about Bayer possibly halting U.S Roundup sales without legal protections.
BAYER Stocks News Analytics from Fri, 16 Aug 2024 07:00:00 GMT to Fri, 11 Apr 2025 12:13:24 GMT -
Rating -8
- Innovation -3
- Information 3
- Rumor -7
